The Latest Breaking News from BMY

The S&P 500 Index ($SPX ) (SPY ) today is down -1.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.49%. March E-mini S&P futures (ESH26 ) are down -1.29%, and March E-mini Nasdaq futures...

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.